Company OHR Pharmaceutical Inc Nasdaq
Equities
US67778H3093
Biotechnology & Medical Research
Business Summary
Managers
Managers | Title | Age | Since |
---|---|---|---|
Todd Branning
CEO | Chief Executive Officer | 54 | 09/01/22 |
Dani Stoltzfus
PRN | Corporate Officer/Principal | - | - |
Ron Sarkar
PRN | Corporate Officer/Principal | - | 31/10/21 |
Alan Scrivner
LAW | General Counsel | - | 31/08/21 |
Shannon McCarthy
HRO | Human Resources Officer | - | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Dov Goldstein
CHM | Chairman | 56 | 11/07/19 |
Eric Richman
BRD | Director/Board Member | 63 | 11/07/19 |
Director/Board Member | 79 | 11/07/19 | |
Gerald McDougall
BRD | Director/Board Member | 57 | 10/05/21 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 3,751,590 | 3,249,699 ( 86.62 %) | 0 | 86.62 % |
Company contact information
NeuBase Therapeutics, Inc.
350 Technology Drive Suite 421
15219, Pittsburgh
+
http://www.neubasetherapeutics.comSector
1st Jan change | Capi. | |
---|---|---|
+25.69% | 47.86B | |
+46.90% | 41.42B | |
-3.46% | 40.66B | |
-6.20% | 28.92B | |
+9.17% | 25.55B | |
-20.42% | 19.27B | |
+0.17% | 12.15B | |
+28.07% | 12.14B | |
-1.24% | 11.99B |